Importantly, our analysis and the data from Loddo et al. show that at least 50% of ER-positive BC express PLK1 at high levels, suggesting that the proportion of patients that would benefit from a PLK1 targeting agent would be significant37. This evidence concerns the gene PLK1 and breast cancer.